The treatment will begin with 70 mg PO twice a day (BID), giving continuous daily doses. The subjects will receive treatment until progression of the disease despite having escalated the dose to the highest level considered safe, intolerable toxicity or until the study is withdrawn.
Sponsors
BRISTOL MYERS SQUIBB COMPANY,
Unknown Phase
PHASE II STUDY OF BMS-354825 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A BLASTIC LYMPHOID PHASE OR WITH ACUTE LYMPHOBLASTIC LEUKEMIA POSITIVE PHILADELPHIA CHROMOSOME THAT ARE REFRACTORY OR INTOLERANT TO THE IMATINIB MESILATE TREATMENT
Active, not recruitingPER-016-05
Updated: 2023-09-04
Phase II Study of BMS-354825 in Patients with Chronic Myeloid Myeloid Phase Ieloblastic Leukemia Who Are Resistant or Intolerant to Treatment with Imatinib Mesylate
Active, not recruitingPER-015-05
Updated: 2023-09-04